Lung adenocarcinoma (LUAD), a predominant subtype of non‐small cell lung cancer (NSCLC), is commonly treated with targeted therapies or chemotherapy, depending on the presence of specific driver mutations such as those in the epidermal growth factor receptor (EGFR) gene. This evidence concerns the gene EGFR and non-small cell lung carcinoma.